US stocks fluctuate | Eli Lilly (LLY.US) rose more than 2%, Zepbound's weight loss effect is much better than Wegovy

According to ZhuTong Finance APP, on Monday, Eli Lilly (LLY.US) rose more than 2% to $752.61. In terms of news, on May 11th local time, Lilly announced comparative trial data showing that its weight loss drug Zepbound has a weight loss effect nearly 50% higher than its competitors Novo and Novartis' similar drug Wegovy.